India–EU FTA Boosts Opportunities for Pharma and Medical Devices Sector

The India–European Union Free Trade Agreement marks a major step forward for India’s pharmaceutical and medical device industries. Union Minister for Chemicals and Fertilisers J.P. Nadda said the agreement will open access to the European Union’s $572.3 billion pharma and MedTech market, creating strong growth opportunities for Indian manufacturers.

Easier Market Access and Lower Tariffs

Under the India–EU FTA, Indian pharmaceutical products and Made in India medical devices will benefit from preferential market access and reduced tariffs. This move is expected to accelerate growth in high-value segments and improve India’s competitiveness in the European market.

Looking For a Medical Device Regulatory Consultant?

Let’s have a word about your next project

Strengthening India’s Role as a Global Healthcare Partner

The agreement supports India’s position as the “pharmacy of the world” by helping companies scale operations, expand exports, and generate employment. It also strengthens India’s integration into global supply chains, making Indian healthcare products more accessible and reliable worldwide.

Big Gains for MSMEs and Manufacturing Hubs

The FTA is expected to benefit MSMEs through increased participation, capacity expansion, and cluster development. Key manufacturing hubs such as Gujarat, Maharashtra, Karnataka, and Andhra Pradesh are likely to see significant growth across pharmaceuticals, medical devices, chemicals, fertilisers, cosmetics, soaps, and detergents.

Coastal Export Hubs to See Export-Led Growth

Coastal regions are set to gain from increased exports, supporting employment and processing-intensive industries. Improved trade flow with the EU will further strengthen India’s export infrastructure and logistics ecosystem.

Aligned with Viksit Bharat 2047 Vision

Aligned with India’s Viksit Bharat 2047 vision, the India–EU Free Trade Agreement promotes innovation, shared values, and sustainable growth. It lays the foundation for a future-ready, resilient, and inclusive economic partnership between India and Europe.

About Operon Strategist

Operon Strategist is a global regulatory and consulting partner supporting pharmaceutical and medical device companies across the entire product lifecycle. We provide end-to-end services including FDA 510(k) and PMA support, CE marking and UKCA approvals, ISO 13485 certification, MDSAP consulting, CDSCO and global market registrations, QMS implementation, design control documentation, cleanroom validation, manufacturing setup guidance, and regulatory strategy consulting. With strong expertise across India, the EU, the UK, and the USA, Operon Strategist helps startups, MSMEs, and established manufacturers achieve faster approvals, maintain compliance, and scale confidently in global healthcare markets.